Uveal Melanoma

Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal Melanoma Patients (PLUME)

This Phase II, single-centre trial aims to evaluate the combination of pembrolizumab and lenvatinib in patients with metastatic uveal melanoma (UM). Researchers suspect that prior treatment with Tebentafusp may influence the effectiveness of anti-PD-1 therapies. To investigate this, the study will include two separate groups: Both cohorts will receive the same treatment, and the study […]

Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal Melanoma Patients (PLUME) Read More »

Study of Roginolisib in UM Patients (OCULE-01)

This Phase II study is being conducted at multiple centres to evaluate the effectiveness of a drug called Roginolisib in treating advanced or metastatic ocular/uveal melanoma. The study is open-label, meaning all participants will know they are receiving the treatment, and participants will be randomly assigned to different treatment groups to assess the anti-tumour activity

Study of Roginolisib in UM Patients (OCULE-01) Read More »

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass)

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass) Read More »

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD)

Researchers are exploring better ways to manage people with intermediate or high-risk resected cutaneous melanoma or primary uveal melanoma. This study is investigating the use of a new blood test to guide when to administer a drug called tebentafusp. Tebentafusp has previously been tested in clinical trials for patients with advanced cutaneous and uveal melanoma.

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD) Read More »

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

This Phase 1/2 multi-centre, open-label basket study aims to assess the safety and effectiveness of IDE196 in treating solid tumours with specific genetic changes, such as GNAQ or GNA11 mutations or PRKC fusions. The study includes patients with metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other types of solid tumours.

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Read More »

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Phase 2 multi-center open-label IDE196 study in patients with primary uveal melanoma requiring either enucleation or plaque brachytherapy. Patients will be treated in neoadjuvant setting up to 6 months (or maximum benefit) followed by primary local therapy. An additional 6 months of adjuvant treatment to follow with long term follow-up (up to 3 years) to

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma Read More »

Skip to content